Hybrid Quinolinyl Phosphonates as Heterocyclic Carboxylate Isosteres: Synthesis and Biological Evaluation against Topoisomerase 1B (TOP1B).
antiproliferative effect
enzyme inhibition
leishmaniosis effect
quinolinyl phosphonates
topoisomerase 1B
Journal
Pharmaceuticals (Basel, Switzerland)
ISSN: 1424-8247
Titre abrégé: Pharmaceuticals (Basel)
Pays: Switzerland
ID NLM: 101238453
Informations de publication
Date de publication:
09 Aug 2021
09 Aug 2021
Historique:
received:
13
07
2021
revised:
03
08
2021
accepted:
06
08
2021
entrez:
28
8
2021
pubmed:
29
8
2021
medline:
29
8
2021
Statut:
epublish
Résumé
This work describes, for the first time, the synthesis of dialkyl (2-arylquinolin-8-yl)phosphonate derivatives. The preparation was carried out through a direct and simple process as a multicomponent Povarov reaction of aminophenylphosphonates, aldehydes, and styrenes and subsequent oxidation with 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ) or, alternatively, by a cycloaddition reaction between phosphonate aldimines and acetylenes. Based on phosphonate group structural characteristics, considered as phosphorous isosteres of carboxylic heterocycles, they may present interesting biological properties related to cell proliferation. In the current report, a new series of dialkyl (2-arylquinolin-8-yl)phosphonates have been synthesized and their antiproliferative effect evaluated on different human cancer and embryonic cells, as well as on
Identifiants
pubmed: 34451880
pii: ph14080784
doi: 10.3390/ph14080784
pmc: PMC8399847
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Ministerio de Ciencia, Innovación y Universidades
ID : RTI2018-101818-B-I00
Organisme : Eusko Jaurlaritza
ID : IT 992-16
Organisme : Ministerio de Economía y Competitividad
ID : SAF2017-83575-R
Références
Expert Opin Ther Pat. 2021 Jun;31(6):473-508
pubmed: 33475439
Pharmaceuticals (Basel). 2019 Jun 10;12(2):
pubmed: 31185654
Chem Rev. 1996 Dec 19;96(8):3147-3176
pubmed: 11848856
Nucleic Acids Res. 2009 Feb;37(3):693-701
pubmed: 19106140
Curr Med Chem. 2019;26(32):5900-5923
pubmed: 29773051
Eur J Med Chem. 2020 Feb 1;187:111970
pubmed: 31881454
Expert Opin Drug Discov. 2016;11(3):281-305
pubmed: 26727036
Expert Opin Drug Discov. 2017 Jun;12(6):583-597
pubmed: 28399679
Int J Parasitol Drugs Drug Resist. 2014 Aug 24;4(3):326-37
pubmed: 25516844
Eur J Med Chem. 2018 May 25;152:137-147
pubmed: 29704722
J Chromatogr B Biomed Appl. 1996 Sep 20;684(1-2):307-21
pubmed: 8906479
Curr Med Chem. 2005;12(26):3127-41
pubmed: 16375706
Drug Discov Today Technol. 2018 Nov;29:71-79
pubmed: 30471676
Curr Top Med Chem. 2014;14(23):2722-8
pubmed: 25515747
J Med Chem. 2006 Oct 19;49(21):6177-96
pubmed: 17034125
Mol Cancer Ther. 2006 Feb;5(2):287-95
pubmed: 16505102
Annu Rev Biochem. 2001;70:369-413
pubmed: 11395412
J Med Chem. 2005 Apr 7;48(7):2336-45
pubmed: 15801827
Nature. 2007 Jul 12;448(7150):213-7
pubmed: 17589503
Eur J Med Chem. 2016 Nov 29;124:740-749
pubmed: 27639365
Eur J Med Chem. 2018 Apr 10;149:225-237
pubmed: 29501943
J Biol Chem. 2003 Feb 7;278(6):3521-6
pubmed: 12444094
Biochemistry. 1998 Jul 28;37(30):10815-27
pubmed: 9692972
Eur J Med Chem. 2015 Jun 5;97:871-910
pubmed: 25073919
J Org Chem. 2017 Jun 16;82(12):6379-6387
pubmed: 28537387
Cancer Sci. 2014 Apr;105(4):370-88
pubmed: 24484288
Expert Opin Drug Discov. 2013 Aug;8(8):1029-47
pubmed: 23646979
PLoS Negl Trop Dis. 2015 Mar 31;9(3):e0003666
pubmed: 25826250
Bioorg Chem. 2020 May;98:103732
pubmed: 32171989
Eur J Med Chem. 2016 Jun 10;115:179-90
pubmed: 27017547
Eur J Med Chem. 2019 Jan 15;162:18-31
pubmed: 30408746
Lancet. 2018 Sep 15;392(10151):951-970
pubmed: 30126638
J Mol Model. 2007 Mar;13(3):393-400
pubmed: 17072654
Nat Rev Drug Discov. 2011 Dec 16;11(1):25-36
pubmed: 22173432